Spots Global Cancer Trial Database for A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Official Title: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Study ID: NCT06356311
Conditions
Study Description
Brief Summary: This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108), Marietta, Georgia, United States
Rambam Health Care Campus-Oncology Division ( Site 1600), Haifa, , Israel
Sourasky Medical Center ( Site 1602), Tel Aviv, , Israel
Seoul National University Bundang Hospital ( Site 3504), Seongnam, Kyonggi-do, Korea, Republic of
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3500), Seoul, , Korea, Republic of
Asan Medical Center-Department of Oncology ( Site 3501), Seoul, , Korea, Republic of
Samsung Medical Center-Division of Hematology/Oncology ( Site 3502), Seoul, , Korea, Republic of
The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 3505), Seoul, , Korea, Republic of
National Cheng Kung University Hospital-Clinical Trial Center ( Site 3604), Tainan, , Taiwan
Contact Details
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
